These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 30180806)
1. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806 [TBL] [Abstract][Full Text] [Related]
2. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia. Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H Intern Med; 2018 Sep; 57(17):2451-2458. PubMed ID: 29607963 [TBL] [Abstract][Full Text] [Related]
3. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study. Jia JD; Xie W; Ding HG; Mao H; Guo H; Li Y; Wang X; Wang JF; Lu W; Li CZ; Mao Y; Wang GQ; Gao YQ; Wang B; Zhang Q; Ge Y; Wong VW Ann Hepatol; 2017; 16(1):123-132. PubMed ID: 28051801 [TBL] [Abstract][Full Text] [Related]
4. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan. Kogiso T; Kobayashi M; Yamamoto K; Ikarashi Y; Kodama K; Taniai M; Torii N; Hashimoto E; Tokushige K Intern Med; 2017 Nov; 56(22):2993-3001. PubMed ID: 28943585 [TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228 [TBL] [Abstract][Full Text] [Related]
6. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579 [TBL] [Abstract][Full Text] [Related]
7. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029 [TBL] [Abstract][Full Text] [Related]
8. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C; N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757 [TBL] [Abstract][Full Text] [Related]
9. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879 [TBL] [Abstract][Full Text] [Related]
10. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis. Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495 [TBL] [Abstract][Full Text] [Related]
11. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial. Wang YF; Tang JT; Han T; Ding HG; Ye WJ; Wang MR; Cheng J; Yang YP; Chen CW; Xie Q; Mao Q; Niu JQ; Wang ZH; Wei Z; Chen YX; Zeng M; Mao YM J Dig Dis; 2018 Mar; 19(3):144-154. PubMed ID: 29389068 [TBL] [Abstract][Full Text] [Related]
12. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822 [TBL] [Abstract][Full Text] [Related]
13. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT). Verbalis JG; Ellison H; Hobart M; Krasa H; Ouyang J; Czerwiec FS; Am J Kidney Dis; 2016 Jun; 67(6):893-901. PubMed ID: 26874645 [TBL] [Abstract][Full Text] [Related]
14. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. Tang J; Wang Y; Han T; Mao Q; Cheng J; Ding H; Shang J; Zhang Q; Niu J; Ji F; Chen C; Jia J; Jiang X; Lv N; Gao Y; Wang Z; Wei Z; Chen Y; Zeng M; Mao Y BMC Gastroenterol; 2020 Nov; 20(1):391. PubMed ID: 33213378 [TBL] [Abstract][Full Text] [Related]
15. Tolvaptan for the treatment of liver cirrhosis oedema. Sakaida I Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622 [TBL] [Abstract][Full Text] [Related]
16. Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. Pose E; Solà E; Piano S; Gola E; Graupera I; Guevara M; Cárdenas A; Angeli P; Ginès P Am J Med; 2017 Mar; 130(3):372-375. PubMed ID: 27746291 [TBL] [Abstract][Full Text] [Related]
17. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan. Gaglio P; Marfo K; Chiodo J Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834 [TBL] [Abstract][Full Text] [Related]
18. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Nemerovski C; Hutchinson DJ Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957 [TBL] [Abstract][Full Text] [Related]
19. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study. Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675 [TBL] [Abstract][Full Text] [Related]
20. Long-term administration of Tolvaptan to patients with decompensated cirrhosis. Kanayama K; Chiba T; Kobayashi K; Koroki K; Maruta S; Kanzaki H; Kusakabe Y; Saito T; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Yasui S; Kanda T; Maruyama H; Kato J; Kato N Int J Med Sci; 2020; 17(7):874-880. PubMed ID: 32308540 [No Abstract] [Full Text] [Related] [Next] [New Search]